Is RVMD a good stock to buy? We came across a bullish thesis on Revolution Medicines, Inc. on Two Natural Capital’s Substack. In this article, we will summarize the bulls’ thesis on RVMD. Revolution Medicines, Inc.'s share was trading at $93.21 as of March 26th. Is RVMD a good stock to buy? Photo by National Cancer Institute on Unsplash Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. RVMD is advancing a differentiated ap ...

Core Insights - Revolution Medicines, Inc. is set to present nine oral and poster presentations at the AACR Annual Meeting, showcasing advancements in its RAS(ON) inhibitor pipeline for RAS-addicted cancers [1][4] Presentation Highlights - New Phase 1 data for zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be featured in a plenary session, focusing on patients with previously treated KRAS G12D mutant non-small cell lung cancer [2] - Two Phase 1/2 datasets evaluating daraxonrasib, a RAS(ON) multi-selective inhibitor, will be presented, including monotherapy and combination therapy data with chemotherapy for first-line metastatic pancreatic ductal adenocarcinoma [3] - Additional presentations will cover preclinical research on a new class of mutant-targeted catalytic RAS(ON) inhibitors, aimed at maintaining antitumor activity despite resistance [4] Presentation Details - An invited presentation titled "Targeting the Oncogenic State of RAS: Lessons from Tri-Complex Inhibitors" will be given by Dr. Mallika Singh on April 18 [6] - An oral presentation on the preliminary safety and clinical activity of zoldonrasib will be presented by Dr. Jonathan Reiss on April 19 [7] - A mini-symposium will feature daraxonrasib plus chemotherapy as a first-line treatment for metastatic pancreatic adenocarcinoma, presented by Dr. Brian Wolpin on April 21 [8] - Additional poster presentations will cover various aspects of RAS(ON) inhibitors and their effects on cancer and immune cells [10] Company Overview - Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, with a pipeline that includes multiple RAS(ON) inhibitors currently in clinical development [12]

Tango Therapeutics (NasdaqGM:TNGX) 2026 Conference March 11, 2026 03:00 PM ET Company ParticipantsMalte Peters - President and CEOConference Call ParticipantsAndrew Berens - Senior Research AnalystAndrew BerensAndrew Berens, Senior Biotech Analyst, Targeted Oncology at Leerink Partners. Very excited to have with us Tango Therapeutics, the CEO, Malte Peters. Thank you for joining us.Malte PetersThank you, Andy. Thanks Leerink for having us. We are excited to be here and share some updates on our end.Andrew B ...

Key Takeaways TNGX shares surged 36.3% to a record high after ERAS announced a clinical trial collaboration and supply deal.ERAS will supply ERAS-0015 while TNGX sponsors a phase I/II combo study in MTAP-deleted RAS-mutant cancers.TNGX plans to initiate a pivotal study of vopimetostat monotherapy in MTAP-deleted pancreatic cancer in 2026.Shares of Tango Therapeutics (TNGX) surged 36.3% on Thursday to a record high after Erasca (ERAS) announced a clinical trial collaboration and supply agreement with the com ...

Summary of Conference Call Transcript Company Overview - **Company**: Tango Therapeutics - **Key Product**: Vopimetostat, a PRMT5 inhibitor with potential in treating various cancers, particularly pancreatic cancer Core Industry Insights - **Cancer Treatment Landscape**: Focus on high unmet medical needs and fast-to-market opportunities in oncology - **Pipeline Development**: Emphasis on developing combination therapies and exploring multiple cancer indications Key Points and Arguments 1. **Vopimetostat's Potential**: - Vopimetostat is described as a highly potent and selective PRMT5 inhibitor with first and best-in-class potential [1] - Clinically validated with support from the FDA for second-line registration opportunities in pancreatic cancer [1] 2. **Clinical Trials and Data**: - Launching pivotal trial for vopimetostat monotherapy in second-line pancreatic cancer [2] - Combination studies with Revolution Medicines' RAS inhibitors to position vopimetostat as a foundational treatment for frontline pancreatic cancer [2] - Expansion of vopimetostat data in lung cancer and other cancers [3] 3. **Market Opportunity**: - Approximately 60,000 patients with MTAP deletion in the U.S. could benefit from PRMT5 inhibition annually [5] - High prevalence of MTAP deletions in various cancers: 15% in non-small cell lung cancer, 40% in pancreatic cancer, 45% in glioblastoma [5] 4. **Safety and Efficacy**: - Vopimetostat shows a benign safety profile with only 8% dose reductions and no grade 4 or 5 related events observed [8] - Median progression-free survival (PFS) of 7.2 months in pancreatic cancer, doubling standard care expectations [9] - Objective response rate of 49% in histology-selective cohort with a median PFS of 9.1 months [11] 5. **Combination Therapy Strategy**: - Initiated combination trials with zoldonrasib and daraxonrasib, targeting RAS mutations in pancreatic cancer [12] - Over 90% of pancreatic cancers are RAS-driven, presenting a significant market opportunity [14] 6. **Financial Position**: - Company has a strong financial position with $343 million in cash, providing a runway into 2028 [16] 7. **Future Milestones**: - Upcoming data releases on vopimetostat and combination therapies later this year [17] - Plans to start a second-line pivotal trial in pancreatic cancer and provide updates on TNG456, a CNS penetrant PRMT5 inhibitor [16] Additional Important Insights - **First-Mover Advantage**: Tango is the first company to combine a PRMT5 inhibitor with a RAS inhibitor, potentially paving the way for innovative treatment pathways [6] - **Patient-Centric Approach**: Focus on developing treatments for patients with high unmet medical needs, particularly in aggressive cancers [4]

Summary of Revolution Medicines FY Conference Call Company Overview - **Company**: Revolution Medicines (NasdaqGS: RVMD) - **Industry**: Biotechnology, specifically focused on targeted therapies for RAS-driven cancers, particularly pancreatic cancer Key Value Creation Events - The most significant upcoming event is the readout of the **RASolute 302 trial** for daraxonrasib in previously treated pancreatic cancer, expected in the first half of 2026 [3][4] - Five Phase 3 studies are underway, with four focused on pancreatic cancer [3] Trial Insights - The RASolute 302 trial design includes a core cohort of patients with G12 mutations, which represent about 85% of pancreatic cancer cases [7] - Two potential analyses will be conducted: one for the core cohort and another including all pancreatic cancer patients [8] - Possible outcomes include passing progression-free survival (PFS) and overall survival (OS) statistical significance, with varying implications for data presentation [9][10] Treatment Strategy - Revolution Medicines emphasizes the importance of RAS suppression across all treatment lines, asserting that RAS-driven characteristics persist regardless of treatment history [12][13] - Initial data from previously treated pancreatic cancer patients show promising response rates compared to chemotherapy [14] Regulatory and Commercialization Plans - The company is prepared for a swift NDA submission following positive trial results, having established manufacturing and regulatory processes [20][21] - A National Priority Voucher from the FDA is expected to expedite the review process [20] - An educational campaign, "Expect RAS," aims to inform practitioners about RAS-driven pancreatic cancer [22] Enrollment and Patient Access - Enrollment for the first-line trial is anticipated to be rapid once operational processes are complete, with high demand for daraxonrasib from patients [28][29] - The trial design includes a control arm, which may lead to patient dropouts if they prefer alternative treatments [33][34] Importance of Overall Survival - Establishing OS is crucial for regulatory approval and market uptake, with the company aiming to demonstrate survival benefits in both first and second-line treatments [40][41] Ongoing and Future Trials - Multiple trials are being conducted for different RAS inhibitors, including zoldonrasib, which is well-tolerated and shows promise in combination with chemotherapy [54] - The company is exploring various treatment combinations to address the diverse needs of pancreatic cancer patients [53] Market Considerations - There is skepticism regarding the commercial potential of later-line lung cancer therapies, but Revolution Medicines believes their RAS inhibitors can significantly improve patient outcomes compared to existing standards of care [69] Colorectal Cancer Developments - The company is optimistic about finding a path forward in colorectal cancer but has not provided specific timelines or details on upcoming data [73] This summary encapsulates the key points discussed during the Revolution Medicines FY Conference Call, highlighting the company's strategic focus on RAS-driven cancers and its plans for upcoming trials and regulatory submissions.

Company Overview - Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company focused on developing novel targeted therapies for cancer treatment [4] Investment Potential - Revolution Medicines has been initiated with an Outperform rating and a price target of $140 by Evercore ISI, indicating strong buy potential [1] - The company is expected to launch daraxonrasib, which is seen as a potential breakthrough in oncology, with key Phase 3 data for pancreatic cancer anticipated in the first half of 2026 [1] Financial Performance - As of December 31, 2025, Revolution Medicines reported cash, cash equivalents, and marketable securities totaling $2.0 billion [2] - Research and development expenses for Q4 were $294.9 million, up from $188.1 million in the previous year, attributed to increased clinical trial and manufacturing costs for daraxonrasib, zoldonrasib, and elironrasib, as well as higher personnel-related expenses [3]

Core Insights - Revolution Medicines (RVMD) reported a Q4 2025 loss of $1.86 per share, which is wider than the Zacks Consensus Estimate of a loss of $1.56, and a significant increase from a loss of $1.12 in the same quarter last year [1][7] - The company has no approved products and did not generate any revenues in 2025 [5][8] - RVMD's stock fell 5% in after-market trading following the earnings report, despite a year-to-date increase of 30%, outperforming the industry growth of 10% [1][2] Financial Performance - Research and development expenses for Q4 2025 were $294.9 million, reflecting a nearly 57% year-over-year increase, driven by higher costs for clinical studies and manufacturing [3] - General and administrative expenses reached $66.7 million, up more than 136% year-over-year, primarily due to increased commercial preparation activities and employee-related expenses [3] - For the full year 2025, the company reported a loss of $5.95 per share, wider than the $3.58 loss from the previous year [8] Cash Position - As of December 31, 2025, Revolution Medicines had cash and cash equivalents of $2 billion, an increase from $1.9 billion as of September 30, 2025 [4] 2026 Guidance - RVMD expects operating expenses for 2026 to be between $1.6 billion and $1.7 billion, which includes non-cash stock-based compensation expenses of $180-$200 million [9] Pipeline Developments - The company is advancing daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, into multiple late-stage studies for pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) [10][12] - The RASolute 302 study is assessing daraxonrasib in second-line metastatic PDAC, while the RASolute 303 study is evaluating its efficacy in the first-line setting [11] - RVMD has initiated the phase III RASolute 305 study to evaluate the combination of zoldonrasib with chemotherapy in first-line PDAC patients [14] Strategic Collaborations - To enhance its pipeline, Revolution Medicines has entered into collaborations with companies like Summit Therapeutics and Tango Therapeutics to evaluate combinations of its RAS(ON) inhibitors with their drugs [15] - A recent collaboration with Bristol Myers Squibb aims to evaluate daraxonrasib in combination with navlimetostat for certain pancreatic cancer patients [16]

Management is pivoting toward a global oncology enterprise, transitioning from a discovery-focused biotech to a commercial-stage organization with 8 ongoing or planned Phase III trials. The 'virtuous cycle' of innovation is driven by the tri-complex platform, which has enabled the rapid advancement of four clinical-stage RAS(ON) inhibitors targeting major oncogenic drivers. Pancreatic cancer remains the primary strategic focus, with daraxonrasib showing an unprecedented clinical profile that earned FD ...

Financial Data and Key Metrics Changes - The company ended Q4 2025 with $2.03 billion in cash and investments, having entered a strategic partnership with Royalty Pharma that provided access to up to $2 billion in committed capital [21] - R&D expenses for Q4 2025 were $294.9 million, up from $188.1 million in Q4 2024, primarily due to increased clinical trial and manufacturing expenses [21][22] - G&A expenses for Q4 2025 were $66.7 million, compared to $28.2 million in Q4 2024, driven by commercial preparation activities and increased personnel-related expenses [22] - The net loss for Q4 2025 was $364.9 million, compared to $194.6 million in Q4 2024, attributed to higher operating expenses [22][23] - Full year 2026 GAAP operating expenses are expected to be between $1.6 billion and $1.7 billion, reflecting the expansion of clinical development programs [24] Business Line Data and Key Metrics Changes - The company has advanced its pipeline with four novel investigational drugs targeting major oncogenic RAS drivers, including daraxonrasib, elironrasib, zoldonrasib, and RMC-5127 [8][9] - There are currently eight ongoing or planned phase 3 registrational trials, with over 2,500 patients having received one or more RAS(ON) inhibitors [8] Market Data and Key Metrics Changes - The company is focusing on pancreatic cancer, where over 90% of cases are RAS-driven, and has multiple registrational trials underway or planned for 2026 [9][10] - The FDA has granted daraxonrasib Breakthrough Therapy Designation, highlighting its potential to address significant unmet needs in pancreatic cancer [10] Company Strategy and Development Direction - The company aims to revolutionize treatments for RAS-addicted cancers through innovative targeted medicines and has established a strong operational foundation for a successful commercial launch [7][20] - The company is committed to advancing its RAS(ON) inhibitor pipeline and exploring novel approaches to overcome RAS-driven drug resistance [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of their pipeline to transform treatment standards for difficult-to-treat cancers, with key milestones expected in 2026 [26] - The company is preparing for its first commercial launch, initially focused on the U.S. market, and has made strategic hires to support this effort [20] Other Important Information - The company is exploring collaborations with other firms to evaluate RAS(ON) inhibitors in combination with new targeted therapies [16][17] - The company has initiated a clinical collaboration with Bristol Myers Squibb to evaluate daraxonrasib in combination with navlimetostat in pancreatic cancer patients [17] Q&A Session Summary Question: Plans to advance daraxonrasib combination in first-line non-small cell lung cancer - Management confirmed a high commitment to continue developing daraxonrasib in lung cancer, particularly in the first line, with ongoing dose optimization and efficacy testing [30][31] Question: Efficacy measure for the second-line PDAC trial - Management indicated that the study is powered for overall survival (OS) and progression-free survival (PFS), but no specific expectations could be provided at this time [36] Question: Impact of daraxonrasib use in first-line studies on OS outcomes - Management acknowledged potential complications with crossover from the control arm but emphasized that they expect to establish significant momentum before FDA review [41][42] Question: Ongoing partnered collaborations and decision-making for late-stage trials - Management explained that decisions about advancing into late-stage trials will be data-driven, considering the emerging combination data and the broader landscape of ongoing trials [48] Question: Treatment beyond progression in PDAC - Management noted that while treatment beyond progression is not permitted in the RASolute 302 study, they encourage evaluation of this possibility in other studies [78]